NKGen Biotech, Inc. Reports Third Quarter 2023 Financial
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease,...
United States Chris Calabrese Kevin Gardner Denise Chua Corporate Communications Exchange Commission
Source: globenewswire.com